GLP-1 and SSRIs: depression, suicidal-ideation review and what the MHRA actually found

MHRA and EMA both reviewed the 2023 to 2024 reports of suicidal ideation on GLP-1 medications, and both found no causal link. The signal appears to reflect the background rate of mental-health events in people starting weight-loss treatment, not a drug effect. If you take an SSRI, GLP-1 can be used alongside sertraline, escitalopram, fluoxetine and other common ones. Screen at baseline and keep monitoring. Reflexive avoidance is not the answer.

What the reviews examined

In 2023, the FAERS (US) and Eudravigilance (EU) databases showed an uptick in reported suicidal ideation among GLP-1 patients. The MHRA (UK) and the EMA (Europe) each opened a formal review, and both closed in 2024 with the same finding.

The MHRA looked at spontaneous reports of suicidal ideation, suicide attempts and self-harm on semaglutide, liraglutide and tirzepatide, the reporting rate per 100,000 patient-years against background rates in obesity and diabetes, and a causality assessment using standard pharmacovigilance methods. Its conclusion: "No causal association established between GLP-1 receptor agonists and suicidal ideation or self-injury." The reporting rate sat above the drug's background but tracked media-driven reporting bias. The obesity and T2D population already carries higher baseline depression and suicidality. The timing of symptoms relative to starting the drug did not fit a pharmacological cause, and no mechanistic link has been shown.

The EMA's PRAC committee reached the same result in April 2024: no change to GLP-1 product information. It noted that all patients should be monitored for depression and suicidal thoughts as part of standard care, but called that general practice, not GLP-1-specific.

In the US, the FDA's own FAERS analysis through 2024 agreed. Wegovy and Zepbound each once carried a warnings-and-precautions note on suicidal behavior and ideation. Novo Nordisk and Lilly removed it in February 2026, and both labels list the removal in their recent major-changes tables. The boxed warning for thyroid C-cell tumors stays on Wegovy, Zepbound and Ozempic. See the Wegovy label and the Zepbound label.

What it means if you take an SSRI

There is no causal link to worsened mood and no documented interaction between common SSRIs (Lexapro, Zoloft, Prozac, Celexa, Paxil) and GLP-1. The combination is widely prescribed without a specific adverse-event signal. Tell your telehealth clinician you take an SSRI at intake, and tell your psychiatrist or PCP you are starting a GLP-1. Weight changes can affect the dosing of weight-sensitive drugs like lithium, and new GI symptoms can affect SSRI absorption, so both prescribers want to know. Do not stop the SSRI, change its dose, or add St. John's Wort, which interacts with SSRIs.

If your mood worsens in the first 8 to 12 weeks, most of that traces to GI side effects, fatigue or the stress of calorie restriction rather than the GLP-1 itself. Talk to both clinicians before you attribute it to the drug.

When to treat the mood disorder first

Obesity itself is independently linked to higher depression and suicidality. If you are starting a GLP-1 with active depression, get psychiatric care in place first. The drug does not substitute for treating the mood disorder. For active suicidal ideation, stabilize psychiatric care before adding any new medication, the same rule that applies to statins or blood-pressure drugs. GLP-1 has shown weak antidepressant effects in some observational studies, likely from the weight loss and metabolic gains, but it is not approved for depression, where SSRIs and SNRIs remain first-line.

Programs set up for SSRI patients

Most telehealth GLP-1 programs accept SSRI patients. The ones best equipped for psychiatric comorbidity are Knownwell (full primary care, coordinates with your psychiatrist), Form Health (obesity-medicine specialists) and 9amHealth (cardiometabolic, SSRI co-management). Cash-pay compounded programs like Mochi, Henry Meds and Medvi will take SSRI patients too, but their model is transactional, not psychiatric-coordinated. Fine if your mental-health care is well-managed elsewhere.

See the full score and today's price for coordinated care on the Knownwell review page.